Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
about
Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart diseaseAntidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesThe Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including AtherosclerosisStructures of Human DPP7 Reveal the Molecular Basis of Specific Inhibition and the Architectural Diversity of Proline-Specific PeptidasesFibroblast activation protein α in tumor microenvironment: recent progression and implications (review)Saxagliptin overview: special focus on safety and adverse effectsIdentification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (part I): virtual screening and activity assaysThe Concise Guide to PHARMACOLOGY 2013/14: enzymes.Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retentionPharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetesPleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemSerum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo.Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.The pathophysiology of hypertension in patients with obesity.Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose.A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation.Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetesDipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells.Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes.Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies.Proteomics in the characterization of adipose dysfunction in obesity.DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes.Dipeptidyl peptidase IV is a human and murine neutrophil chemorepellentMaladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance.Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro.Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.Recent patents of dipeptidyl peptidase IV inhibitors.Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine.DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation.DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.Identifying natural substrates for dipeptidyl peptidases 8 and 9 using terminal amine isotopic labeling of substrates (TAILS) reveals in vivo roles in cellular homeostasis and energy metabolism.Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.
P2860
Q26752511-29137AC8-67FD-42EF-A35B-C81D0BF2B730Q26784211-473E3435-FEB8-4990-900D-0189F39869C5Q26785454-F4EB337A-CA0E-4899-938D-511A69A22005Q26795473-16542FAC-1240-4CE6-AF70-2B1C681DF8CAQ27672453-0EA576C0-38C4-4BF4-9B67-E10E1E1A552CQ28082504-E28E7DD6-A439-4D30-8FA1-16CEDA200683Q28278863-D9EE3FE4-A3B6-48D6-9A91-AB9B8297E91CQ28483681-CEDC7FA1-B9A7-41F1-AA29-442EA4688F22Q30486745-F1B4E52B-A65F-4557-A37F-24438161FA74Q30717371-09E431D7-B308-4F71-A499-A6EB24C30C85Q33566802-83B79E0F-8CBE-40E3-876B-F2729A6E485BQ34062829-EA4255CD-1F03-4DA5-8E1D-ADB0AE0B77EAQ34386621-937CD0AA-8B04-4261-9675-65090CDFAA1BQ34681579-A9D140C1-FDA7-4415-B8F4-E271BC731330Q35021492-C537A8D9-62B6-4AFD-91C8-590DC8A797D6Q35063234-CF9C03D5-D749-43F3-9FF6-BA28A22BD333Q35855698-3F62B06E-EB1D-4AB5-BFB1-D57551E6C00DQ36477217-DD6AADD8-C1F8-4AAD-809C-DA650C8245E0Q36520758-2E15300B-EBBE-4370-A89E-806E78206C24Q36687153-3917B560-C771-4CFB-88AD-D66FEE609E01Q36694480-41DAAEB0-C3AC-4DBF-8A3E-E377C940D341Q36797503-90F426E6-87CB-4CCA-8C32-915DCD31F817Q36833317-4A3EEB26-7DD3-4C4A-AD17-6DB109744B45Q36866103-7F5296B2-9F33-4D7E-A6C0-7A7FACC5A886Q37095161-34AE1615-42C8-413C-AD44-96CE8A71782CQ37130392-ED6A81BA-663F-45B2-A36E-7E4E68114576Q37258157-3CE37788-6FF3-4DD8-8DAB-B7525094CD31Q37331331-768FF5B9-932E-4A6A-8569-90AE8672DEFDQ37910902-DF07FA03-CF59-463B-AAA0-496EC3E292BCQ37948110-526C5729-508F-4875-A145-91B6FFA18862Q38107546-BDE24090-55BF-4292-8D23-AFB0E70EC90AQ38205588-319E5B58-AFA9-4CFE-BD66-09D30F80FA95Q38315999-9C4AFB08-85A2-4565-972F-EA18D4D594F6Q38670397-DC77B820-C527-4B4C-81CC-4997BE9CB89CQ38751579-32FC737B-AD76-4277-B59F-A9F42814A48FQ38814125-64FB6197-84E2-4923-84EA-8B08F431A579Q38870486-A9935946-5C09-46A1-ACE9-4CCED28D68ECQ38922177-B85C88EA-87F2-4B50-982D-4D280149ABA4Q39177343-7A0BAEE1-F7BD-40EE-AA69-7E640F55631EQ39377477-AC8D3B42-8DAC-46C7-92C0-7D98F1B0B5AA
P2860
Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
@en
Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
@nl
type
label
Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
@en
Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
@nl
prefLabel
Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
@en
Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
@nl
P2093
P1476
Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
@en
P2093
Catherine A Abbott
Gordon S Howarth
Roger Yazbeck
P304
P356
10.1016/J.TIPS.2009.08.003
P577
2009-11-01T00:00:00Z